Elevation Oncology (NASDAQ:ELEV – Free Report) had its price objective trimmed by HC Wainwright from $6.00 to $1.00 in a ...

HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Avalo Therapeutics in a research report issued to ...

Lyell Immunopharma’s (LYEL) jumped over 8% on Friday as investors’ interest surged. Despite posting unimpressive Q4 results a ...

Fintel reports that on March 21, 2025, HC Wainwright & Co. downgraded their outlook for OptiNose (NasdaqGS:OPTN) from Buy to ...

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Barinthus Biotherapeutics (BRNS – Research Report) today and set a price target of ...

SAN FRANCISCO, March 20, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced that the company will be webcasting its participation in the H.C. Wainwright 3rd Annual Autoimmune & ...

About VYNE Therapeutics Inc. VYNE is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high ...

HC Wainwright initiated coverage on Alpha Cognition, noting a new twist on a tried-and-tested treatment paradigm.

Fintel reports that on March 17, 2025, HC Wainwright & Co. initiated coverage of Actuate Therapeutics (NasdaqGM:ACTU) with a ...